Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Osteogenic transdifferentiation of primary human fibroblasts to osteoblast-like cells with human platelet lysate

ABSTRACT: Osteogenic transdifferentiation of primary human fibroblasts to osteoblast-like cells with human platelet lysate

PROVIDER: PRJNA851430 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19769869.fastq.gz	Fastqsanger.gz
	SRR19769870.fastq.gz	Fastqsanger.gz
	SRR19769871.fastq.gz	Fastqsanger.gz
	SRR19769872.fastq.gz	Fastqsanger.gz
	SRR19769873.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Osteogenic transdifferentiation of primary human fibroblasts to osteoblast-like cells with human platelet lysate

Project description:Inherited bone disorders account for about 10% of documented Mendelian disorders and are associated with high financial burden. Their study requires osteoblasts which play a critical role in regulating the development and maintenance of bone tissue. However, bone tissue is not always available from patients. We developed a highly efficient platelet lysate-based approach to directly transdifferentiate skin-derived human fibroblasts to osteoblast-like cells. We extensively characterized our in vitro model by examining the expression of osteoblast-specific markers during the transdifferentiation process both at the mRNA and protein level. The transdifferentiated osteoblast-like cells showed significantly increased expression of a panel of osteogenic markers. Mineral deposition and ALP activity were also shown, confirming their osteogenic properties. RNA-seq analysis allowed the global study of changes in the transcriptome of the transdifferentiated cells. The transdifferentiated cells clustered separately from the fibroblasts with regard to the significantly upregulated genes indicating a distinct transcriptome profile; transdifferentiated osteoblasts also showed significant enrichment in gene expression related to skeletal development and bone mineralization. Our presented in vitro model may potentially contribute to the prospect of studying osteoblast-dependent disorders in patient-derived cells.

2022-06-24 | GSE206594 | GEO

Osteogenic transdifferentiation of primary human fibroblasts to osteoblast-like cells with human platelet lysate.

Project description: Not available

| S-EPMC9424276 | biostudies-literature

Mesenchymal stromal cells in platelet lysate versus fetal calf serum

Project description:Mesenchymal stromal cells in platelet lysate versus fetal calf serum

| PRJNA347630 | ENA

Proteomic Characterisation of Human Osteoblast-Derived Decellularised Extracellular Matrix for Osteogenic Repair

Project description:This project investigated cell-derived extracellular matrix (ECM) preparation for matrix-guided bone tissue engineering. A detergent-based decellularisation protocol using NH4OH and Triton X-100 was optimised using fibroblast-derived ECM to improve DNA removal while preserving ECM-associated protein content. To provide a more bone-relevant molecular reference, the same decellularisation approach was also applied to HOB-derived ECM. Proteomic analysis of HOB-derived dECM identified ECM-associated proteins linked to osteogenic activity, including collagens, laminins, annexins, and calcium-binding proteins. This dataset is presented as a descriptive reference for osteoblast-derived ECM composition, rather than as a direct comparison with the fibroblast-derived ECM used in functional assays.

2026-05-26 | PXD077920 | Pride

Induced osteogenic transdifferentiation reprograms malignant phenotypes in pancreatic ductal adenocarcinoma

Project description:Induced osteogenic transdifferentiation reprograms malignant phenotypes in pancreatic ductal adenocarcinoma

| PRJNA1390514 | ENA

Gene expression of mesenchymal stromal cells in platelet lysate versus fetal calf serum

Project description:Culture medium of mesenchymal stromal cells (MSCs) is usually supplemented with either human platelet lysate (HPL) or fetal calf serum (FCS). Many studies have demonstrated that proliferation and cellular morphology is influenced by these additives – hence they may favor outgrowth of specific subpopulations, thereby affecting the heterogeneous composition of MSCs. We have isolated and expanded human bone marrow derived MSCs in parallel with HPL or FCS for two passages. In HPL the proliferation was significantly higher and cells reflected more spindle-shaped morphology. Pairwise comparisons of gene expression profiles (Affymetrix HTA 2.0) revealed only moderate differences. When we apply a fold change >1.5 and limma-adjusted P-value of <0.05, only 69 transcripts were differentially expressed. These results indicate that there is no systematic bias for specific subpopulations of MSCs by using either HPL or FCS.

2017-08-11 | GSE87796 | GEO

DNA methylation of mesenchymal stromal cells in platelet lysate versus fetal calf serum

Project description:Culture medium of mesenchymal stromal cells (MSCs) is usually supplemented with either human platelet lysate (HPL) or fetal calf serum (FCS). Many studies have demonstrated that proliferation and cellular morphology is influenced by these additives – hence they may favor outgrowth of specific subpopulations, thereby affecting the heterogeneous composition of MSCs. We have isolated and expanded human bone marrow derived MSCs in parallel with HPL or FCS for two passages. In HPL the proliferation was significantly higher and cells reflected more spindle-shaped morphology. In contrast, global DNA-methylation profiles did not reveal any significant differences. None of the CpGs revealed significant differences between MSCs that were cultured in HPL versus FCS if the analysis was corrected for multiple testing (limma-adjusted P-value of <0.05). These results indicate that there is no systematic bias for specific subpopulations of MSCs by using either HPL or FCS.

2017-08-11 | GSE87797 | GEO

Stimulated Human Platelet Lysate: control, PAR1 and PAR4 stimulated

Project description:LC-MS/MS analysis of Control, PAR1-stimulated and PAR4-stimulated platelet lysate digests. Control lysate digest peptides were labeled with "light", PAR1 lysate digest peptides were labeled with "intermediate" and PAR4 lysate digest peptides were labeled with "high" dimethyl labeled. Labeled digests were mixed in a 1:1:1 ratio, separated by SCX and the resulting (phosphopeptide-enriched) peptide fractions were analyzed by LC-MS/MS.

2016-05-11 | PXD000228 | Pride

Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis

Project description:Human adult mesenchymal stromal cells (hMSC) have the potential to differentiate into chondrogenic, adipogenic or osteogenic lineages, providing a potential source for tissue regeneration. An important issue for efficient bone regeneration is to identify factors that can be targeted to promote the osteogenic potential of hMSCs. Using transcriptomic analysis, we found that integrin alpha5 (ITGA5) expression is upregulated during dexamethasone-induced hMSCs osteoblast differentiation. Gain-of-function studies showed that ITGA5 promotes the expression of osteoblast phenotypic markers as well as in vitro osteogenesis in hMSCs. Downregulation of endogenous ITGA5 using shRNA blunted osteoblast marker expression and osteogenic differentiation. Pharmacological and molecular analyses showed that the enhanced hMSCs osteoblast differentiation induced by ITGA5 was mediated by activation of FAK/ERK1/2-MAPKs and PI3K signaling pathways. Remarkably, activation of ITGA5 using a specific antibody that primes the integrin or a peptide that specifically activates ITGA5 was sufficient to enhance ERK1/2-MAPKs and PI3K signaling and to promote osteoblast differentiation and osteogenic capacity of hMSCs. We also demonstrate that hMSCs engineered to over-express ITGA5 exhibited a marked increase in their osteogenic potential in vivo. These findings not only reveal that ITGA5 is required for osteoblast differentiation of adult human MSCs but also provide a novel targeted strategy using ITGA5 agonists to promote the osteogenic capacity of hMSCs, which may be used for tissue regeneration in bone disorders where the recruitment or capacity of MSCs is compromised. Keywords: Time course of osteogenic differentiation processes

2009-09-10 | GSE18043 | GEO

Induced osteogenic transdifferentiation reprograms malignant phenotypes in pancreatic ductal adenocarcinoma

Project description:This study characterizes transcriptional changes associated with osteogenic induction in pancreatic ductal adenocarcinoma (PDAC) cell lines. Capan-2 and PANC-1 cells were cultured under control conditions or osteogenic induction and collected at day 0, day 7, and day 14. Bulk RNA sequencing was performed to identify gene expression dynamics during osteogenic reprogramming. Analyses revealed activation of osteogenic markers and related pathways, along with suppression of cell-cycle programs. These datasets provide a transcriptomic framework for understanding osteogenic plasticity in PDAC cells.

2026-06-18 | GSE314240 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data